Brodalumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Kyntheum® |
| INN | Brodalumab |
| API type | Monoclonal antibody |
| Pharmacotherapeutic group | Immunosuppressants, Interleukin inhibitors. |
| ATC code | L04AC12 |
| Target of antibody | IL-17RA |
| General function | Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E (also known as IL-25), resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Elevated levels of IL-17A, IL-17C and IL-17F gene expression are found in psoriatic plaques. Elevated levels of expression of IL-12B and IL-23A, the genes for the two subunits of IL-23, an upstream activator of IL-17A and IL-17F expression, are also found in psoriatic plaques. |
| Original license holder | LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Denmark |
| Marketing authorisation numbers | EU/1/16/1155/001, EU/1/16/1155/002 |
| Marketing authorisation holder | LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Denmark |
| Name of the manufacturer of the biological active substance | Immunex Rhode Island Corporation 40 Technology Way, West Greenwich, Rhode Island, 02817 United States |
| Name and address of the manufacturer(s) responsible for batch release | Laboratoires LEO 39 route de Chartres 28500 Vernouillet France LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Denmark |
| Max shelf life | 4 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Proline Glutamate Polysorbate 20 Water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
